We postulate psoriasis pathogenesis is driven by the circadian clock and that timing the delivery of current treatments, and novel therapies such as anti‐VEGF‐A agents, could enhance their effectiveness in patients with psoriasis. This evidence concerns the gene VEGFA and psoriasis.